[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Centro de Atenção ao Assoalho Pélvico\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":162},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,45,69,95,120,138],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":29,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100541953","microablative-radiofrequency-in-the-treatment-of-urinary-symptoms-associated-with-genitourinary-syndrome-of-menopause-100541953",false,"NCT06336564","Microablative Radiofrequency in the Treatment of Urinary Symptoms Associated With Genitourinary Syndrome of Menopause","Microablative Radiofrequency in the Treatment of Urinary Symptoms Associated With Genitourinary Syndrome of Menopause: Randomized Clinical Trial","Inclusion Criteria:\n\n* Clinical complaint of urinary incontinence associated to Genitourinary Syndrome of Menopause.\n* Negative cervical oncotic cytology, within the last 3 years.\n\nExclusion Criteria:\n\n* Patients with cognitive deficit;\n* Patients with chronic degenerative neurological diseases;\n* Post-void residue greater than 50 ml;\n* Carriers of a pacemaker and implantable cardioverter defibrillator;\n* Use of hormonal therapy (topical or systemic) starting in the 2 months prior to the initial assessment;\n* Patients undergoing brachytherapy or pelvic radiotherapy;\n* Patients that had reconstructive pelvic surgery;\n* Pregnant women.","FEMALE","40 Years","65 Years",{"count":20,"type":21},40,"ESTIMATED","INTERVENTIONAL",[24],"NA","Genitourinary Syndrome fo Menopause (GSM) is made up of a set of changes in the region of the vulva, vagina and lower urinary tract associated with a decrease in estrogen levels in the urogenital tissue, which leads to a reduction in blood supply, disorders in collagen metabolism and skin elasticity. The standard treatment for urinary incontinence during menopause is pelvic floor muscle training, associated or not with local hormone replacement therapy. Although low cost and easy to access, it is associated with low patient's adherence. Physical methods such as laser and radiofrequency in non-ablative, ablative and microablative forms are technologies that have recently been used in the vaginal mucosa to promote neoelastogenesis and neocollagenesis. It is hypothesized that menopausal women, who present symptoms of GSM, may benefit from this new, minimally invasive resource (microablative radiofrequency). This is a randomized clinical trial in which women aged between 40 and 65 years old will be included with clinical complaints of urinary symptoms associated with GSM. A basic anamnestic questionnaire will be used as the study instrument to collect sociodemographic, clinical data and symptoms, following the routine and standard of the service. To evaluate the treatment, the following will be used: voiding diary, pad test, vaginal cytology, histopathology, Female Sexual Function Index (FSFI), Short-Form Health Survey - SF-36 Questionnaire, King's Health Questionnaire, evolution of symptoms (dryness, pain during sexual activity, vaginal laxity, itching, burning sensation and pain in the vaginal introitus) and level of patient's satisfaction. Patients will be randomized into: group 1 or control group, which will perform pelvic floor muscle training, PFMT, with supervision (three times) and at home twice a day, and group 2 or test group, which will perform the same PFMT protocol associated with vaginal microablative radiofrequency. 10% lidocaine spray will be applied three minutes before the procedure and three applications will be made to the vagina\u002Fvaginal introitus, with an interval of 30 to 40 days. The purpose of this study is to test the efficacy and duration of effect of microablative radiofrequency in the treatment of urinary symptoms associated with GSM.",[27,28],"Menopause","Urinary Incontinence",[30,31],"Genitourinary syndrome of menopause","Microablative Radiofrequency","NOT_YET_RECRUITING","2024-08-19",{"date":35,"type":36},"2024-08-20","ACTUAL",{"date":38,"type":21},"2025-08",{"date":40,"type":21},"2027-12",{"name":42,"class":43},"Centro de Atenção ao Assoalho Pélvico","OTHER",1,{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":4,"eligibilityCriteria":51,"healthyVolunteers":11,"sex":16,"minAge":52,"maxAge":18,"enrollmentInfo":53,"targetDuration":4,"studyType":22,"phases":55,"briefSummary":56,"conditions":57,"keywords":59,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":62,"startDateStruct":64,"completionDateStruct":66,"leadSponsor":68,"locationsCount":44},"100542021","light-emitting-diode-in-the-treatment-of-vulvodynia-100542021","NCT06337448","Light Emitting Diode in the Treatment of Vulvodynia","Light Emitting Diode in the Treatment of Vulvodynia: a Pilot Study","Inclusion Criteria:\n\n* vulvodynia diagnosis\n\nExclusion Criteria:\n\n* patients diagnosed with vaginal infection\n* difficulty in understanding the proposed instruments\n* patients with chronic degenerative neurological diseases\n* pregnant women","18 Years",{"count":54,"type":21},10,[24],"Vulvar pain can be related to a specific cause (inflammation, cancer, trauma, infection) or can be classified as vulvodynia, when vulvar pain is idiopathic and lasts for at least three months. The main symptoms reported are pain, burning, erythema, increased sensitivity, itching and burning, which affect the quality of life, psycho-emotional well-being, relationships and sexual function of these women. Photobiomodulation has been described in the literature as an alternative to treat pain. Our group has studied blue LED for some vulvovaginal dysfunctions and, due to the positive sensory effects observed in patients with vaginal stenosis and genitourinary syndrome of menopause, it is hypothesized that this technique could also bring beneficial effects for women with vulvodynia. A pilot study will be carried out, with descriptive data, with 10 women with vulvodynia. Participants will be evaluated with a basic anamnestic questionnaire and sociodemographic data. The following questionnaires will be used: Female Sexual Function Index (FSFI), Sexual Quotient - Female Version, Vulvar Pain Assessment Questionnaire. After answering the questionnaires, the volunteer will undergo a perineal physical assessment by an experienced physiotherapist, which includes a) inspection of the genital region, reflex tests, assessment of the functions of the pelvic floor muscles, b) the cotton swab test to evaluate painful sensitivity in the vestibule, c) the tampon test to evaluate painful sensitivity in the introitus and vaginal canal. Pain assessments will be quantified by the visual analogue pain scale (VAS), which ranges from 0 (no pain) to 10 (maximum pain). At the end of the treatment, the participant will answer the questionnaires again, undergo reassessment of pain sensitivity in vulva, introitus and vaginal canal, of the function of the pelvic floor muscles and will be asked \"What is your perception of improvement\" and \"What is your level of satisfaction with the treatment?\". The answers will be giving according to a Likert Scale of five points. The LED application protocol will be carried out with external use equipment model Antares, from the company IBRAMED (Amparo, São Paulo, Brazil), with a cluster G2 applicator. The power will be 450mW\u002Fcm2 and dose 5J\u002Fcm2 for 2 minutes and 13 seconds (automatic programming) in 450nm waves (blue wavelength). The treatment consists of eight sessions, carried out daily, except on weekends.",[58],"Vulvodynia",[60,61],"vulvodynia","Light-emitting diode",{"date":63,"type":36},"2024-08-21",{"date":65,"type":21},"2025-08-16",{"date":67,"type":21},"2026-12",{"name":42,"class":43},{"id":70,"slug":71,"hasResults":11,"nctId":72,"briefTitle":73,"officialTitle":74,"acronym":4,"eligibilityCriteria":75,"healthyVolunteers":11,"sex":76,"minAge":52,"maxAge":77,"enrollmentInfo":78,"targetDuration":4,"studyType":22,"phases":79,"briefSummary":80,"conditions":81,"keywords":83,"overallStatus":86,"whyStopped":4,"lastUpdateSubmitDate":87,"lastUpdatePostDateStruct":88,"startDateStruct":90,"completionDateStruct":92,"leadSponsor":94,"locationsCount":44},"100539424","non-ablative-radiofrequency-and-low-intensity-shock-wave-therapy-in-fibrotic-plaque-in-men-with-peyronies-disease-100539424","NCT06303661","Non-ablative Radiofrequency and Low Intensity Shock Wave Therapy in Fibrotic Plaque in Men With Peyronie's Disease","Non-ablative Radiofrequency and Low-intensity Shock Wave Therapy in Fibrotic Plaque in Men With Peyronie's Disease: Case Series","Inclusion Criteria:\n\n* Clinical complaint related to Peyronie's disease;\n* At any stage of the disease (acute or chronic).\n\nExclusion Criteria:\n\n* Users of a pacemaker, cardiac defibrillator implant or any other electromagnetic implant;\n* Metallic implants over or under the area to be treated.","MALE","80 Years",{"count":54,"type":21},[24],"The goal of this one arm clinical trial is to evaluate the safety and describe the clinical response of non-ablative radiofrequency treatment associated with shockwave therapy in men with Peyronie's disease. The main question\\[s\\] it aims to answer are: • is the treatment safe? • is there any clinical response to the proposed treatment? Participants will respond to five validated questionnaires: International Index of Erectile Dysfunction (IIEF-5), Medical Outcomes Study 36 - Item Short - Form Health Survey (SF-36), Peyronie's Disease Questionnaire (PDQ), Scale Hospital for Anxiety and Depression (SHAD) and the Erection Quality Questionnaire (EQQ); will undergo a physical assessment that includes palpation of the fibrotic plaque on the penis, pharmacological induction of erection, and assessment of the size of the fibrotic plaque through ultrasound. Every five sessions, the participant's degree of satisfaction will be measured using a 5-point Likert scale, as well as the evolution of symptoms will also be observed, using a 10-point Visual Analogue Scale (VAS) and penile pain, if present. The entire evaluation protocol will be applied before (pre-test), after treatment (post-test) and 1 month after the end of treatment. Volunteers will be monitored by telephone to verify the long-term response after 3, 6, 9 and 12 months of completed treatment in relation to the Likert scale and VAS. The treatments they'll be given are • of monopolar non-ablative radiofrequency associated with • low-intensity shock wave therapy.",[82],"Peyronie Disease",[82,84,85],"Non ablative radiofrequency","Low-intensity Shock Waves Therapy","RECRUITING","2024-05-27",{"date":89,"type":36},"2024-05-29",{"date":91,"type":36},"2024-01-08",{"date":93,"type":21},"2026-06",{"name":42,"class":43},{"id":96,"slug":97,"hasResults":11,"nctId":98,"briefTitle":99,"officialTitle":100,"acronym":101,"eligibilityCriteria":102,"healthyVolunteers":11,"sex":16,"minAge":52,"maxAge":103,"enrollmentInfo":104,"targetDuration":4,"studyType":22,"phases":106,"briefSummary":107,"conditions":108,"keywords":109,"overallStatus":86,"whyStopped":4,"lastUpdateSubmitDate":87,"lastUpdatePostDateStruct":114,"startDateStruct":115,"completionDateStruct":117,"leadSponsor":119,"locationsCount":44},"100539420","effects-of-non-ablative-radiofrequency-on-female-genito-pelvic-pain-disorder-100539420","NCT06303609","Effects of Non-ablative Radiofrequency on Female Genito-pelvic Pain Disorder","Effects of Non-ablative Radiofrequency on Female Genito-pelvic Pain Disorder: Randomized Clinical Trial","Pelvic Pain","Inclusion Criteria:\n\n* Women with genito-pelvic pain disorder associated to penetration.\n\nExclusion Criteria:\n\n* Chronic degenerative disease\n* Cognitive impairment\n* Genital agenesis\n* History of vaginal cancer or genital radiotherapy\n* Pelvic or lumbosacral prostheses\n* Cardiac pacemakers\n* Pregnant women\n* Infections in the genital or systemic region\n* Any type of treatment for genito-pelvic pain disorder\n* Unstable relationship with the same partner\n* Partner with sexual complaints.","45 Years",{"count":105,"type":21},56,[24],"The goal of this randomized clinical trial is to verify the response of genito-pelvic pain disorders in women associated with inability to penetrate to the treatment with non-ablative radiofrequency. The main question it aims to answer is: Does non-ablative radiofrequency have a positive effect on the symptoms of genito-pelvic pain disorders associated with inability to penetrate? Before starting the intervention and at one week, one-, three- and six months after the end of the study, participants will be evaluated with 03 questionnaires (Female Sexual Function Index, Sexual Quality of Life and Perceived Stress Scale-10) and will score the visual analogue scale the level of pain with the penetration (from 0 to 10); participants will then undergo digital evaluation of the pelvic floor muscles, using vaginal dilators and electromyographic evaluation. After being randomized, participants will be divided into the Experimental Group and the Sham Group, being submitted to • the use of non-ablative radiofrequency in the anal and urogenital triangles, • the positioning of the vaginal dilator at the end of each session • and participants will be instructed to use the vaginal dilator at home daily. The researchers will compare the groups in relation to the ability to penetrate with reduced vaginal pain, sexual function, quality of sexual life and the correlation between pelvic muscle activity and perceived stress.",[101],[110,111,112,113],"genito-pelvic pain disorder","radiofrequency","nonablative radiofrequency","women",{"date":89,"type":36},{"date":116,"type":36},"2024-04-20",{"date":118,"type":21},"2026-07-20",{"name":42,"class":43},{"id":121,"slug":122,"hasResults":11,"nctId":123,"briefTitle":124,"officialTitle":124,"acronym":4,"eligibilityCriteria":125,"healthyVolunteers":11,"sex":16,"minAge":103,"maxAge":18,"enrollmentInfo":126,"targetDuration":4,"studyType":22,"phases":128,"briefSummary":129,"conditions":130,"keywords":4,"overallStatus":86,"whyStopped":4,"lastUpdateSubmitDate":87,"lastUpdatePostDateStruct":132,"startDateStruct":133,"completionDateStruct":135,"leadSponsor":137,"locationsCount":44},"100324637","radiofrequency-non-ablative-in-the-treatment-of-genitourinary-syndrome-of-menopause-100324637","NCT03506594","Radiofrequency Non-ablative in the Treatment of Genitourinary Syndrome of Menopause","Inclusion Criteria:\n\n* will be women in menopause until 65 years of age with clinical complaints of Genitourinary Syndrome of Menopause and who agree to voluntarily participate in the research.\n\nExclusion Criteria:\n\n* will be excluded from the study participants with limited understanding, with neurological degenerative chronic diseases, sensory deficit in the genital region, users of pacemaker and intrauterine device of cooper and women under hormone therapy under six months",{"count":127,"type":21},58,[24],"The study is conducted in women at the menopause with a clinical diagnosis of Genitourinary Syndrome, which presents symptoms in of vulvovaginal atrophy and tract urinary and were treated with radiofrequency non ablative technique for capacitive transfer in intra-vaginal. All participants were evaluated by a physical therapist and did the exam of PH vaginal, cell maturation index and questionnaires. The participants made five sessions of Radio Frequency (RF) with an interval of seven days between them. The application of RF was performed by physical therapist trained in the technique of radio frequency through the Capenergie brand device with capacitive transfer method using non-ablative handle with active electrode intra-vaginal and coupling electrode placed on the participant's back. For application, the participants were in gynecological position. The session had an average duration above 20 minutes. The temperature was measured by an infrared thermometer when it reached 41graus radiofrequency was maintained for 2 minutes in the anterior wall and 2 minutes more in the posterior wall of vagina.",[131],"Genitourinary Syndrome of Menopause",{"date":89,"type":36},{"date":134,"type":36},"2018-04-01",{"date":136,"type":21},"2026-06-20",{"name":42,"class":43},{"id":139,"slug":140,"hasResults":11,"nctId":141,"briefTitle":142,"officialTitle":4,"acronym":4,"eligibilityCriteria":143,"healthyVolunteers":144,"sex":16,"minAge":52,"maxAge":145,"enrollmentInfo":146,"targetDuration":4,"studyType":22,"phases":148,"briefSummary":149,"conditions":150,"keywords":152,"overallStatus":86,"whyStopped":4,"lastUpdateSubmitDate":155,"lastUpdatePostDateStruct":156,"startDateStruct":158,"completionDateStruct":160,"leadSponsor":161,"locationsCount":44},"100256160","the-influence-of-cognitive-behavioral-therapy-in-sexual-dysfunction-female-randomized-clinical-trial-100256160","NCT02613546","THE INFLUENCE OF COGNITIVE BEHAVIORAL THERAPY IN SEXUAL DYSFUNCTION FEMALE: Randomized Clinical Trial","Inclusion Criteria:\n\n* Women aged 18-59 years;\n* FSFI less than or equal to 26.\n\nExclusion Criteria:\n\n* Scores of Beck Scales - moderate or severe;\n* Prescribing hormone therapy after starting the group.",true,"59 Years",{"count":147,"type":21},34,[24],"This research is a randomized clinical trial aims to evaluate the influence of cognitive-behavioral psychotherapy (CBT) on quality of life and sexual function of patients with sexual dysfunction. The notion of sexual health for the World Health Organization exceeds the concept of sickness absence, having a subjective well-being of significance in the spheres of self-concept, self-image, interpersonal relationships and sense of self worth. Furthermore, sexual satisfaction and relationship quality of life is also evidenced in many studies. CBT is a brief and focal psychotherapy with proven efficacy in several mental disorders, improving health and quality of life of the treated populations. However, they did not find clinical trials that showed the effectiveness of CBT in Sexual Dysfunctions. This study aims to then fill this gap by evaluating the relationship from the use of techniques of CBT.",[151],"Sexual Dysfunctions",[153,151,154],"cognitive-behavioral psychotherapy","Women","2023-12-04",{"date":157,"type":36},"2023-12-05",{"date":159,"type":36},"2015-09-10",{"date":67,"type":21},{"name":42,"class":43},""]